8-K: Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split to Regain NASDAQ Compliance

Tonix Pharmaceuticals will implement a 1-for-32 reverse stock split effective June 10, 2024, to meet the NASDAQ's minimum bid price requirement.

Summary

• Tonix Pharmaceuticals has announced a 1-for-32 reverse stock split of its common stock.
• The reverse stock split is scheduled to take effect on June 10, 2024.
• This action is being taken to regain compliance with the NASDAQ's minimum bid price requirement of $1.00 per share.
• The company's stock will begin trading on a split-adjusted basis on the effective date.
• The CUSIP number for the common stock will change to 890260847.
• Fractional shares resulting from the split will be rounded up to the nearest whole share.
• The reverse stock split will not change the number of authorized shares of common stock, which remains at 1,000,000,000.
• As of June 5, 2024, there were 95,543,805 shares of common stock outstanding, which will be reduced to approximately 2,985,744 shares after the split.
• The reverse stock split will also apply to outstanding warrants and stock options, adjusting the number of shares and exercise prices accordingly.
• Shareholders holding shares in electronic form do not need to take any action, while those holding paper certificates may exchange them with the company's transfer agent, vStock Transfer, LLC.

Sentiment

Score: 4

Explanation: The document is primarily a procedural announcement about a reverse stock split, which is generally a negative sign. While necessary for NASDAQ compliance, it reflects past stock price issues and does not indicate positive future performance. The sentiment is therefore slightly negative.

Positives

• The reverse stock split is a necessary step to maintain the company's listing on the NASDAQ Capital Market.
• Rounding up fractional shares ensures that no shareholder will lose out due to the split.
• The company has already obtained shareholder approval for the reverse stock split.

Negatives

• The reverse stock split is a consequence of the company's stock price falling below the NASDAQ's minimum bid price requirement.
• The reverse stock split will significantly reduce the number of outstanding shares, which may be perceived negatively by some investors.

Risks

• The company's stock price may not remain above $1.00 per share even after the reverse stock split.
• The company's future performance is subject to various risks, including those related to clinical trials, regulatory approvals, and market competition.
• The company may need additional financing in the future.

Future Outlook

The company intends to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya. The company also has other product candidates in development in the areas of rare disease and infectious disease. The company's future performance is subject to various risks, including those related to clinical trials, regulatory approvals, and market competition.

Management Comments

• The reverse stock split is intended to increase the per share trading price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. This action is often seen in the biotechnology sector, where companies may experience volatility due to the long and uncertain nature of drug development.

Comparison to Industry Standards

• Many biotechnology companies facing similar listing challenges have implemented reverse stock splits to regain compliance with exchange requirements.
• For example, companies like Agenus Inc. and Ocugen Inc. have recently undergone reverse stock splits to maintain their NASDAQ listings.
• The 1-for-32 ratio is a relatively large split, indicating the severity of the company's stock price decline.
• The success of this strategy will depend on the company's ability to improve its financial performance and investor confidence.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their proportional ownership will remain virtually unchanged.
• The reverse stock split is intended to maintain the company's listing on the NASDAQ, which is important for investor confidence.
• The company's employees may be affected by the company's overall performance and stock price.

Next Steps

• The reverse stock split will be effective on June 10, 2024.
• The company will continue to trade on the NASDAQ Capital Market under the symbol TNXP.
• The company will submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya.

Key Dates

Keywords

reverse stock split, NASDAQ, minimum bid price, TNXP, common stock, stock split, biopharmaceutical, listing compliance